Close Menu

Reverse Genetics-based Recombinant Coronavirus Vaccines


Provided here are compositions for a bacterial artificial chromosome-based construct containing a replication-competent recombinant severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genome and methods of making such compositions and uses thereof. The construct can stimulate an immune response against two or more SARS-CoV-2 strains, such as the original SARS-CoV-2 strain, the Omicron strain, and/or a variant of concern, and can be used as bivalent live attenuated vaccines.

Application Number

63/481,272 (provisional)

Date of Application

January 24, 2023


Luis Martinez-Sobrido, Chengjin Ye, Kevin Chiem, and June Park